Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Spyre Therapeutics (SYRE) Return on Invested Capital: 2022-2023

  • Spyre Therapeutics' Return on Invested Capital was N/A to 46.24% in Q2 2023 from the same period last year, while for Jun 2023 it was 46.24%, marking a year-over-year change of. This contributed to the annual value of -2.06% for FY2023, which is 79.00% down from last year.
  • As of Q2 2023, Spyre Therapeutics' Return on Invested Capital stood at 46.24%, which was up 2,558.61% from -1.88% recorded in Q1 2023.
  • Over the past 5 years, Spyre Therapeutics' Return on Invested Capital peaked at 46.24% during Q2 2023, and registered a low of -1.88% during Q1 2023.
  • In the last 2 years, Spyre Therapeutics' Return on Invested Capital had a median value of -1.28% in 2022 and averaged 10.45%.